Compounded tirzepatide cost: the real number

Advertised prices commonly run about $199 to $349 a month, depending on the provider, dose, and whether a visit is bundled in. But like compounded semaglutide, those headline prices are usually the lowest starting dose and often exclude the consult fee, labs, higher-dose pricing, and shipping — so the real all-in cost frequently lands higher. Ask each provider for the total monthly cost at your target dose, not just the advertised starting price.

Compounded tirzepatide skips FDA approval, brand development, and large-scale manufacturing overhead, so the advertised price is below brand prices. But that discount comes with real trade-offs: it's not FDA-approved, its strength and purity aren't FDA-verified, and it was never studied in trials. It's also worth noting that Zepbound's cash-pay price has dropped — LillyDirect self-pay vials start around $299/mo (2.5 mg) — which narrows the gap versus the FDA-approved option considerably.

Much less than before. The FDA declared the tirzepatide shortage resolved in December 2024, and the enforcement grace periods that let pharmacies compound it widely ended in early 2025. So the flood of cheap compounded tirzepatide has largely receded — compounding can still be legitimate in narrow, individualized situations, but not as a mass-market copy. A site still selling it freely and cheaply is a reason for more caution, not less.

It can be. Legitimate compounding through a properly licensed pharmacy has real costs, and since the shortage ended, mass-market copies are no longer broadly permitted. An unusually low price — especially with no real clinical evaluation, no clear pharmacy information, or no prescription requirement — is a warning sign of an unlicensed or non-compliant seller. Be especially cautious of offers well under $200/month with no questions asked, and confirm the pharmacy and that it's base tirzepatide (not a salt-form variant).

The advertised price is often just the lowest starting dose. Watch for the telehealth consult fee, required lab work, higher-dose pricing (maintenance doses usually cost more), shipping, and any membership fee. A "$199/month" offer can become $300+ once everything is added. Compare each provider's all-in monthly cost at your target dose — and against Zepbound's cash-pay price, which is closer than the headlines suggest.

Often much closer than people expect. Compounded tirzepatide advertises around $99–$450/mo — usually the starting dose, medication only. Zepbound self-pay is $299/month at the 2.5 mg starting dose and $399 at 5 mg, and $449 at 7.5 mg and above if you refill within 45 days. Once a compounded program's consult and lab fees are included, the two can land in a similar range — and only one of them is FDA-approved.

Because compounded pricing is normally tiered by strength, and tirzepatide has more dose steps than semaglutide. A price quoted at the starting dose can be well below what you pay at a maintenance strength months later. Ask for the full price ladder — every strength, not just the first one — before you commit. This is the single biggest gap between the advertised number and the real annual cost.

Almost never. Insurers generally do not cover compounded drugs, so the cash price is the entire price — no copay, no appeal route if it rises. An approved product like Zepbound can be appealed if denied, and can drop to a copay if approved. Find out what your plan would actually charge for the approved product before choosing the compounded path purely on cost.